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Abstract
BACKGROUND—In October 2007, manufacturers voluntarily withdrew over-the-counter 
(OTC) infant cough and cold medications (CCMs) from the US market. A year later, 
manufacturers announced OTC CCM labeling would be revised to warn against OTC CCM use by 
children aged <4 years. We determined whether emergency department (ED) visits for CCM 
adverse drug events (ADEs) declined after these interventions.
METHODS—We used National Electronic Injury Surveillance System-Cooperative Adverse 
Drug Event Surveillance data from 2004 to 2011 to estimate the number of ED visits for CCM 
ADEs before and after each intervention.
RESULTS—Among children aged <2 years, ED visits for CCM ADEs decreased from 4.1% of 
all ADE ED visits before the market withdrawal to 2.4% of all ADE visits afterward (difference in 
proportion: –1.7%, 95% confidence interval [CI]: –2.7% to –0.6%). Among children aged 2 to 3 
years, ED visits for CCM ADEs decreased from 9.5% of all ADE ED visits before the labeling 
revision announcement to 6.5% of all ADE visits afterward (difference in proportion: –3.0%, 95% 
CI: –5.4% to –0.6%). Unsupervised ingestions accounted for 64.3% (95% CI: 51.1% to 77.5%) of 
CCM ADE ED visits involving children aged <2 years after the withdrawal and 88.8% (95% CI: 
83.8% to 93.8%) of visits involving children aged 2 to 3 years after the labeling revision 
announcement.
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CONCLUSIONS—After a voluntary market withdrawal and labeling revision, ED visits for 
CCM ADEs declined among children aged <2 years and 2 to 3 years relative to ADE ED visits for 
all drugs. Interventions addressing unsupervised ingestions are needed to reduce CCM ADEs.
Keywords
adverse events; drug safety; poisoning; medication errors; drug packaging; nasal decongestants; 
expectorants; antitussive agents; product withdrawals; nonprescription drugs
In October 2007, manufacturers voluntarily withdrew oral over-the-counter (OTC) infant 
cough and cold medications (CCMs) intended for use by children <2 years old amid 
considerable publicity.1–4 Studies had not demonstrated CCMs to be more effective than 
placebo in young children but had linked CCMs to significant numbers of emergency 
department (ED) visits and, in rare cases, infant deaths.5–8 The Food and Drug 
Administration (FDA) formally supported this withdrawal in January 2008.9 The next year, 
ED visits and calls to poison centers due to CCM adverse drug events (ADEs) involving 
young children declined.1,10
In October 2008, manufacturers of OTC CCMs announced, with FDA support, that OTC 
CCM labels would be revised to state that the medications should not be used in children <4 
years old.11,12 Media attention and ongoing educational efforts by the FDA,13,14 
professional organizations such as the American Academy of Pediatrics,15 and trade groups 
followed.16 Decreases in calls to poison centers for CCM ADEs involving young children 
were recorded in Texas the following year,17 in Texas and 4 other states through 2010,18 
and nationally through 2010.19 However, national household surveys and surveys of 
caregivers of children treated in EDs indicate that many caregivers still give CCMs to young 
children.20–23
We used nationally representative data to assess whether the 2007 market withdrawal and 
the 2008 labeling revision, along with accompanying publicity and education efforts, were 
associated with persistent, national effects on ED visits for CCM ADEs among children.
METHODS
National estimates of ED visits for ADEs were based on data from the 58 general and 5 
pediatric specialty hospitals that participate in the National Electronic Injury Surveillance 
System-Cooperative ADE Surveillance (NEISS–CADES) project, a nationally 
representative probability sample of hospitals with a minimum of 6 beds and a 24-hour ED 
in the United States and its territories. The NEISS-CADES project is a collaboration of the 
Centers for Disease Control and Prevention, the FDA, and the US Consumer Product Safety 
Commission and has been described in detail previously.24,25 In brief, trained abstractors 
review clinical diagnoses and supporting information in the medical records of each ED visit 
to identify ADEs diagnosed by treating clinicians. Abstractors report up to 2 medications 
implicated in each ADE, concomitant medications listed in the medical record, and narrative 
details of the event. ADE details, including manifestations and physician diagnoses, are 
classified using the Medical Dictionary for Regulatory Activities (MedDRA, version 9.1).
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For this analysis, a case was defined as any ED visit from January 1, 2004, through 
December 31, 2011, by a patient <12 years of age for a problem that was attributed to use of 
a drug or a drug-specific adverse effect and that did not result in the patient’s death either in 
the ED or before arrival. Drugs included prescription and OTC medications, vaccines, and 
herbal remedies/dietary supplements. CCMs included orally administered prescription or 
OTC products containing decongestants, antitussive agents, and/or expectorants alone or in 
combination with each other and/or with analgesics or antihistamines. As part of an 
assessment of possible unintended increases in ADEs from non-CCM drugs after the market 
withdrawal and labeling revision announcement, nasal/ophthalmic decongestants, topical 
analgesics, herbal or alternative medicines, nonprescription analgesics, and antihistamines 
were considered to be drugs potentially substitutable for CCMs by caregivers seeking to 
treat respiratory symptoms. Cases were classified as “unsupervised ingestions” when 
children accessed medications without adult permission or oversight and “supervised 
administrations” when caregivers gave medications to children. ED visits for intentional 
self-harm, drug abuse, therapeutic failures, and drug withdrawal were excluded.
For children <2 years old, the 2007 market withdrawal’s targets, ED visits were considered 
to have occurred before the withdrawal if they happened before October 1, 2007, and to 
have occurred after the withdrawal if they occurred on or after October 1, 2007. ED visits 
involving children 2 to 11 years old were deemed to have occurred before the labeling 
revision announcement if they occurred before October 1, 2008, and to have occurred after 
the revision announcement if they occurred on or after October 1, 2008. We assessed ED 
visits involving children 2 to 11 years old before and after October 1, 2008, because 
previous studies found that the 2007 withdrawal of infant products had not significantly 
affected CCM ADEs among children $2 years old.1,10
Each NEISS-CADES case is assigned a sample weight based on the inverse probability of 
selection. The sample weights are modified for nonresponse rate and poststratified to adjust 
for the number of annual hospital ED visits. The national estimates of ED visits and their 
corresponding 95% confidence intervals (CIs) were calculated with the SURVEYMEANS 
procedure in SAS software, version 9.2 (SAS Institute, Cary, NC), to account for the sample 
weights and complex sample design. To obtain average annual estimates, NEISS-CADES 
estimates for each pre- and postintervention period were divided by the number of months in 
the period and then multiplied by 12. To compare ED visits for CCM ADEs in the pre- and 
postintervention periods, we calculated differences in the proportions of all estimated ADE 
ED visits that were due to CCMs and the corresponding 95% CIs. We compared differences 
in the proportions of ADEs that were due to CCMs to account for any overall increases or 
decreases in pediatric ADE ED visits. To compare the proportions of ED visits for CCM 
ADEs that had particular characteristics in the pre- and postintervention periods, we 
calculated differences in the proportions of ED visits for CCM ADEs with those 
characteristics and the corresponding 95% CIs. Estimated proportions for the respective 
periods were treated as statistically independent because the pre- and postintervention 
periods did not overlap. Estimates <1200 before annualization, based on <20 cases, or 
having a coefficient of variation >30% were considered to be statistically unreliable and are 
noted as such.24
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To further evaluate changes in ED visits for CCM ADEs before and after the interventions, 
we used interrupted time series analysis.26 Trends in the quarterly (3-month) proportions of 
unweighted ADE ED cases that were due to CCMs at hospitals participating continuously in 
NEISS-CADES from 2004 through 2011 were assessed using log binomial regression 
models. The base models included variables reflecting the interventions’ immediate effects 
(ie, change in proportions immediately after the interventions) and slope parameters for 
changes over time before and after the intervention. We then used likelihood ratio statistics 
to assess the incremental statistical improvement from including the slope parameters for 
changes over time in the models. We conducted a sensitivity analysis assessing the effect of 
seasonal variation in CCM ADEs in which the period October 1 through March 31 was 
designated as likely having increased cough and cold ADE incidence.10 The interrupted time 




Between 2004 and 2011, an estimated 61 168 ED visits (95% CI: 47 139–75 196) occurred 
due to CCM ADEs involving children <12 years old. CCMs were the only medications 
implicated in an estimated 93.4% (95% CI: 91.6%–95.3%) of visits, and OTC CCMs 
accounted for more than three-fourths (76.6%) of estimated visits (Table 1). In an estimated 
60.4% (95% CI: 54.3%–66.5%) of ED visits no ADE symptoms were documented. Most 
patients (89.7%, 95% CI: 84.5%–95.0%) did not require admission, observation, or transfer 
to another hospital. However, in an estimated 16.2% of ED visits, gastric decontamination 
was documented to have been given.
Comparing the period before the 2007 market withdrawal to the period after the withdrawal, 
there were no statistically significant differences in the proportions of ED visits for CCM 
ADEs by patient gender, medication marketing category, patient disposition, or the 
documentation of gastric decontamination among children <2 years old. Comparing the 
period before the 2008 labeling revision announcement to the period afterward, among 
children 2 to 3 years old, the proportion of ED visits for CCM ADEs in which gastric 
decontamination was documented declined from 26.0% to 14.1% (difference in proportions: 
–11.9%, 95% CI: –21.7% to –2.1%). Among children aged 2 to 3, 4 to 5, and 6 to 11 years, 
there were no statistically significant differences in the proportions of ED visits for CCM 
ADEs by patient gender, medication marketing category, or patient disposition before and 
after the labeling revision announcement.
Subsequent to the 2007 withdrawal of OTC infant CCM products, among children aged <2 
years, the proportion of ED visits for all ADEs attributed to CCMs decreased by 41%, from 
4.1% of all ADE visits to 2.4% (difference in proportions: –1.7%, 95% CI: –2.7% to –0.6%; 
Table 2). Considering only ED visits resulting from the supervised administration of 
medications, the proportion of ED visits that involved CCMs declined by 55%, from 3.3% to 
1.5% (difference in proportions: –1.8%, 95% CI: –2.9% to –0.6%). Among ED visits for 
unsupervised ingestions of medications, the proportion of all ADE ED visits that involved 
CCMs did not decrease significantly. Unsupervised ingestions accounted for 64.3% (95% 
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CI: 51.1%–77.5%) of ED visits for CCM ADEs involving children <2 years old after the 
withdrawal.
Similarly, among children aged 2 to 3 years, the proportion of ADE ED visits attributed to 
CCMs decreased by 32% from 9.5% of all ADE visits to 6.5% (difference in proportions: –
3.0%, 95% CI: –5.4% to –0.6%) after the 2008 OTC CCM labeling revision announcement 
(Table 3). Among ED visits resulting from the supervised administration of any medication, 
the proportion of ED visits that involved CCMs declined 54% from 5.4% to 2.5% 
(difference in proportions: –2.9%, 95% CI: –5.4% to –0.5%). Considering only ED visits for 
unsupervised ingestions of any medication, the proportion due to CCMs declined 24%, from 
10.8% to 8.2% (difference in proportions: –2.6%, 95% CI: –5.3% to –0.01%). Unsupervised 
ingestions accounted for 88.8% (95% CI: 83.8% to 93.8%) of ED visits for CCM ADEs 
involving children aged 2 to 3 years after the revision announcement.
In contrast to the younger age groups, the proportion of ADE ED visits attributed to CCMs 
did not change significantly after the CCM labeling revision announcement among children 
aged 4 to 5 or 6 to 11 years (Table 3). Unsupervised ingestions accounted for 47.6% (95% 
CI: 31.1%–64.0%) of ED visits for CCM ADEs involving children aged 4 to 5 years after 
the revision announcement. The estimates of ED visits for CCM unsupervised ingestions 
among children aged 6 to 11 years before and after the revision announcement were too 
small to be statistically stable.
After the 2007 market withdrawal, the proportion of supervised administration ADE ED 
visits attributable to potentially substitutable medications did not change significantly 
among children aged <2 years, increasing from 4.8% to 5.0% (difference in proportions: 
0.2%, 95% CI: −1.7% to 2.2%). The proportion of supervised administration ADE ED visits 
attributable to potentially substitutable medications also did not change significantly among 
children aged 2 to 3 years (difference in proportions: −2.4%, 95% CI: −5.7% to 1.0%) after 
the 2008 labeling revision announcement.
Case-Based Interrupted Time Series
In the interrupted time series models, only the variables reflecting the immediate effects of 
the interventions were found to have statistically significant effects on the quarterly 
proportions of unweighted ADE ED cases involving children aged <2 or 2 to 3 years at 
NEISS-CADES hospitals that were due to CCMs. The slope parameters for changes over 
time before and after the interventions were not incrementally statistically significant and 
were therefore removed from the models. Among children aged <2 years, the proportion of 
unweighted supervised administration ADE ED cases that was due to CCMs declined 70.3% 
(95% CI: 55.0%–80.4%; Fig 1); and the proportion of unweighted unsupervised ingestion 
ED cases that was due to CCMs declined 36.2% (95% CI: 14.3%–52.5%). Among children 
aged 2 to 3 years, the proportion of unweighted supervised administration ADE ED cases 
that was due to CCMs declined 56.7% (95% CI: 31.1%–72.7%; Fig 2); and the proportion of 
unweighted unsupervised ingestion ED cases that was due to CCMs declined 31.2% (95% 
CI: 18.2%–42.2%). CCMs were found to account for significantly larger proportions of all 
unweighted ADE ED cases between October and March than between April and September 
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in all models, but this seasonal variation did not significantly change the interventions’ 
estimated effects.
DISCUSSION
After the 2007 OTC infant CCM withdrawal, the 2008 OTC CCM labeling revision 
announcement, and accompanying publicity and education efforts, ED visits for CCM ADEs 
declined for children aged <2 and 2 to 3 years relative to ADE visits due to other drugs. 
Case-based interrupted time series analyses suggest these declines were maintained over the 
3 to 4 years that followed the interventions. After the market withdrawal and labeling 
revision announcement, unsupervised ingestions were implicated in nearly two-thirds of ED 
visits for CCM ADEs among children aged <2 years and nearly 90% among children aged 2 
to 3 years.
The market withdrawal and labeling revision were directed primarily at preventing ADEs 
from the intentional administration of CCMs to children by caregivers. Although ED visits 
to treat ADEs from supervised administration of CCMs have not been eliminated, they have 
declined as a proportion of ED visits for ADEs from the supervised administration of all 
medications by 55% among children aged <2 years and 54% among children aged 2 to 3 
years. However, in a recent survey many parents of children aged 0 to 3 years (25%–44%) 
reported that they had given their child a CCM the last time the child had upper respiratory 
tract infection symptoms.21 Efforts to educate parents and medical providers on CCMs’ 
risks for children aged <4 years by the FDA,14 CCM manufacturers,16 and professional 
organizations, such as the American Academy of Pediatrics’ contribution to the Choosing 
Wisely campaign,27 may help to reduce the number of ADEs from supervised 
administration of CCMs, but additional interventions are needed to further decrease CCM 
ADEs among children.
Reducing CCM ADEs among young children requires prevention of unsupervised 
ingestions. National estimates of ED visits for unsupervised ingestions of CCMs by children 
<2 years old did not decline after infant products were withdrawn, and unsupervised 
ingestions now account for most ED visits for CCM ADEs among children aged both <2 
years and 2 to 3 years. Improved packaging designed to limit young children’s access to 
medications holds potential for reducing unsupervised ingestions.28 For example, adding 
flow restrictors to bottles can reduce young children’s ability to access liquid medications.29 
Unsupervised ingestions could also be reduced through safer medication handling and 
storage practices as promoted by the American Association of Poison Control Centers,30 
Safe Kids Worldwide,31 and the Up and Away and Out of Sight campaign.32 FDA efforts to 
remove from the market prescription CCMs that lack adequate evidence of safety and 
efficacy may also reduce CCM ADEs.33
Both the withdrawal of OTC infant CCMs and the labeling revision warning against use of 
OTC CCMs by children <4 years old could have caused unintended consequences. Each 
intervention had the potential to increase ADEs from other medications (eg, antihistamines 
or nonnarcotic analgesics) that could be substituted for OTC CCMs. In this analysis, neither 
intervention was associated with a significant increase in ED visits for ADEs from 
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supervised administrations of drugs potentially substitutable for CCMs. In addition, calls to 
poison centers regarding prescription CCM therapeutic errors involving children <2 years 
old, which could have been substituted for OTC CCMs, declined through 2009.34
The fact that relative declines in ED visits for CCMADEs occurred after the market 
withdrawal and the labeling revision announcement does not prove causal relationships 
between the interventions and declines. Nevertheless, several pieces of evidence suggest that 
these interventions exerted important effects. First, in contrast to children aged <2 or 2 to 3 
years, there were no significant relative declines in ED visits from CCM ADEs among 
children aged 4 to 5 or 6 to 11 years, suggesting that the declines among younger children 
resulted from the targeted interventions and not broader secular trends. Second, in the 
interrupted time series modeling of changes in CCM ADEs over time, all slope parameters 
that were independent of the interventions had nonsignificant effects. Finally, although 
limited to voluntary reports and covering different time periods, 5 studies based on poison 
center calls have found that CCM ADEs began declining only after the withdrawal of OTC 
infant CCMs.10,17–19,34
These findings are subject to several limitations. First, the data do not include ADE cases if 
the affected individual was not brought to the ED. However, in general, ED-based data may 
best capture outpatient ADE cases involving concern for serious harm. Second, NEISS-
CADES data collection relieson ED physicians’ assessments and documentation and is 
therefore more likely to identify well-recognized ADEs than ADEs that are rare, previously 
unknown, or difficult to diagnose in EDs.24,25 Nevertheless, it is unlikely that lack of 
recognition caused the observed declines in CCM ADE ED visits because awareness of 
CCMs’ risks has probably increased since 2007. Third, the interrupted time series analysis 
reflects only changes in unweighted cases at sampled hospitals and without weighting 
should not necessarily be assumed to represent national trends. Fourth, the pre- and 
postintervention analyses’ results could have been affected by a seasonal imbalance. The 
months from January through September accounted for a slightly larger proportion of the 
period before the interventions than the period after the intervention, and the months from 
October through December accounted for a larger proportion of the periods after the 
interventions. However, the interrupted time series analysis suggests that the seasonal 
variations’ influence on the interventions’ effects were minor. In addition, the reduction in 
the estimated average annual number of ED visits for CCM ADEs after the interventions 
despite the 2009 H1N1 influenza pandemic during the postintervention period provides 
reassurance that the declines were not due to a lower average incidence of upper respiratory 
tract infections in the periods after the interventions.35,36 Finally, ED visit data cannot 
differentiate the effects of the market withdrawal and the labeling revision announcement 
from the effects of the media attention and public education efforts that accompanied them.
Although progress has been made in reducing ADE ED visits from supervised 
administrations of CCMs, more remains to be done to decrease all types of CCM ADEs 
among children. Addressing unsupervised ingestions has the greatest potential for further 
reductions in CCM ADEs. Public health surveillance will continue to be important for 
tracking the effects of efforts to reduce CCMADEs and for identifying future opportunities 
for reducing the burden of ADEs in the United States.
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WHAT’S KNOWN ON THIS SUBJECT
In 2007, manufacturers voluntarily withdrew over-the-counter (OTC) infant cough and 
cold medications (CCMs) from the US market. A year later, manufacturers announced 
OTC CCM labeling would be revised to warn against OTC CCM use by children aged <4 
years.
WHAT THIS STUDY ADDS
Among children aged <2 and 2 to 3 years, emergency department visits for CCM adverse 
events declined nationally after the withdrawal and labeling revision announcement 
relative to all adverse drug event visits. Unsupervised ingestions caused most CCM 
adverse events after each intervention.
Hampton et al. Page 11














Quarterly proportion of ED supervised administration ADE unweighted cases due to CCMs 
among children aged <2 years, NEISS-CADES continuously participating hospitals, 2004–
2011. CCMs include oral prescription or OTC products containing decongestants, 
antitussive agents, and/or expectorants alone or in combination with each other and/or with 
analgesics or antihistamines. Modeled quarterly (3-month) proportions of ED ADE cases 
due to CCMs are based on interrupted time series binomial regression of immediate effects 
of the 2007 product withdrawal.
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Quarterly proportion of ED supervised administration ADEs unweighted cases due to CCMs 
among children aged 2 to 3 years, NEISS-CADES continuously participating hospitals, 
2004–2011. CCMs include oral prescription or OTC products containing decongestants, 
antitussive agents, and/or expectorants alone or in combination with each other and/or with 
analgesics or antihistamines. Modeled quarterly (3-month) proportions of ED ADE cases 
due to CCMs are based on interrupted time series binomial regression of immediate effects 
of the 2008 labeling revision announcement.
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TABLE 1
Numbers of Cases and National Estimates of Adverse Events From CCMs Among Children Aged <12 Years 
Treated in EDs According to Case Characteristics: United States, January 1, 2004 Through December 31, 
2011
Case Characteristics Cases, n National Estimate of ED Visits
n % 95% CI
Patient age, y
  <2 295 14 516 23.7 19.3–28.2
  2–3 645 30 747 50.3 45.7–54.8
  4–5 179 8766 14.3 11.6–17.1
  6–11 151 7138 11.7 8.9–14.5
Patient gender
  Female 597 29 613 48.4 43.9–52.9
  Male 673 31 555 51.6 47.1–56.1
Medication marketing category
  OTC 1008 46 875 76.6 72.1–81.2
  Prescription 168 9622 15.7 11.2–20.3
  Unknown 94 4671 7.6 5.2–10.1
ED treatment and disposition
  Gastric decontamination 224 9929 16.2 12.0–20.5
  Treated and released or left against medical advice 1048 54 872 89.7 84.5–95.0
Adverse event manifestation
  No symptoms documented 742 36 973 60.4 54.3–66.5
  Allergic reaction 236 13 011 21.3 16.2–26.4
  Neurologic 195 7331 12.0 8.2–15.8
  Gastrointestinal 79 2538 4.1 2.6–5.7
  Behavioral 56 1948 3.2 1.6–4.8
Total 1270 61 168 100
Case counts and estimates from National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance, Centers for 
Disease Control and Prevention. CCMs include orally administered prescription or OTC products containing decongestants, antitussive agents, 
and/or expectorants alone or in combination with each other and/or with analgesics or antihistamines.
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